利福喷丁、利福平在初治涂阳肺结核患者治疗中的疗效

目的 探讨利福喷丁、利福平治疗初治涂阳肺结核患者的疗效.方法 选取沈阳市第十人民医院2019年1—12月收治的90例初治涂阳肺结核患者作为研究对象,采用随机数字表法分为对照组与观察组,每组45例.对照组采用利福平治疗,观察组采用利福喷丁治疗,比较两组患者痰涂片转阴率、空洞闭合治疗有效率,发热、咳嗽、咳痰症状消退时间,治...

Analysis of the Curative Effect of Rifapentin and Rifampicin in the Treatment of Newly Treated Smear-Positive Pulmonary Tuberculosis Patients

Objective To explore the effects of rifapentin and rifampicin on newly-treated smear-positive pulmonary tuberculosis patients. Methods A total of 90 patients of newly-treated smear-positive pulmonary tuberculosis patients admitted to Shenyang Tenth People’s Hospital from January 2019 to December 2019 were selected as the research objects, and were divided into a control group and an observation group by random number table method, with 45 cases in each group. The control group Rifampicin was used for treatment, and the study group was treated with rifapentin. The sputum smear conversion rate, cavity closure rate, fever,cough, sputum and other symptoms disappeared, the incidence of adverse reactions during the treatment and the treatment were compared between the two groups There is always efficiency. Results The sputum smear conversion rate(91.11%), the total effective rate of cavity closure(93.33%) and the total effective rate of treatment(93.33%) in the study group were significantly higher than those in the control group(75.56%),(82.22%),(77.78%), the time for the patients in the study group to resolve symptoms such as fever, cough, and sputum(20.04±2.15) d,(21.56±2.09) d,(26.74±2.16) d was significantly shorter than that of the control group(48.18±3.49) d,(52.77±3.24) d,(70.23±3.78) d, the incidence of adverse reactions(2.22%) during treatment in the study group was significantly lower than that in the control group(15.56%), and the comparison between the two groups was statistically significant(P<0.05). Conclusion Compared with rifampicin, rifapentin is more effective in the treatment of newly treated smear-positive pulmonary tuberculosis patients, and has lower toxicity. Therefore, it is worthy of clinical priority use and promotion.